Patient-derived disease models have emerged as critical tools for biological research. Specifically, patient-derived xenograft models (PDXs), generally provide higher fidelity representations of the underlying cancer than cell lines. The Jain T-cell lymphoma research team has expertise in generating PDX models and is continually expanding their repository of PDX models representing diverse subtypes of T-cell lymphoma. Cancer cell lines are the most widely, efficient and scalable systems for validating candidates and defining preclinical efficacy. Organoids are the miniatures of in vivo tissues, and faithfully recapitulate the architectures. Their co-cultures with immune cells can be leveraged to screen immunotherapeutic compounds for personalized medicine. Through an ongoing collaboration with the Cancer Cell Line Factory at the Broad Institute, we are developing cell lines and organoids for rare types of T-cell lymphoma such as hepatosplenic T-cell lymphoma, T-prolymphocytic leukemia, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma among others.